TransCode Therapeutics Inc. RNAZ
1.69
0.04
2.42%
as of 25 Sep
- Market cap
- $27.9M
- P/E
- 0.0×
Follow RNAZ
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
6.29 | 2.56 | 1.28 | 1.70 | 8.97 | 2.05 | 3.25 | — |
Net Debt/EBITDA |
0.64 | 0.38 | 0.15 | 0.27 | 3.41 | (1.73) | (1.58) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 197.72% | 428.15% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.61) | (0.85) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.54 | 0.79 | 0.97 | 0.90 | 0.77 | 0.21 | 0.84 | — |
Capex/Depreciation |
(0.06) | (0.04) | (0.07) | (1.02) | (5.92) | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (872.24%) | 8,883.62% | (759.85%) | (148.57%) | (80.53%) | 104.04% | 27.03% | — | |
| (42.75%) | (269.34%) | (290.74%) | (115.08%) | (57.04%) | (368.51%) | (560.41%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(192.31%) | (383.84%) | (1,708.53%) | (542.01%) | (33.54%) | (549.82%) | (428.81%) | — |
Average Days of Receivables |
0.00 | — | — | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(28.31) | (1,060.14) | (90,550.50) | 0.00 | (0.65) | (0.11) | (0.79) | — |
Cash per Share |
25.83 | 461.20 | 13,838.00 | 0.00 | 2.47 | 0.18 | 0.32 | — |
Shareholders Equity per Share |
14.99 | (160.21) | 8,204.00 | 0.00 | 2.42 | (0.74) | (1.70) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
14.99 | (160.21) | 8,204.00 | 0.00 | 2.42 | (0.74) | (1.70) | — |
Free Cash Flow |
(19.52) | (13.36) | (18.11) | (15.86) | (5.52) | (0.49) | (0.51) | — |
Working Capital |
18.49 | 4.32 | 0.96 | 3.03 | 20.20 | 0.43 | 0.14 | — |
Capital Expenditures |
(0.01) | (0.02) | (0.04) | (0.10) | (0.25) | — | — | — |
Net Current Asset Value |
(130.08) | (2.22) | 0.93 | 3.03 | 20.20 | (3.63) | (1.11) | — |
| Other line items | ||||||||
Quick Ratio |
5.37 | 2.10 | 0.79 | 1.23 | 8.22 | 2.04 | 3.25 | — |
Depreciation/Fixed assets |
0.31 | 10.37 | 4.28 | 0.47 | 0.21 | — | — | — |
Cash ROIC |
(70.65%) | (353.01%) | (412.74%) | (194.55%) | (13.27%) | 99.90% | (1,461.21%) | — |
Accounts Receivable Turnover |
0.00 | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(28.30) | (1,058.41) | (90,372.50) | 0.00 | (0.63) | (0.11) | (0.79) | — |
Capex per Share |
(0.01) | (1.73) | (178.00) | 0.00 | (0.03) | 0.00 | 0.00 | — |
Average Receivables |
0.66 | — | — | — | — | — | — | — |
Average Payables |
3.10 | 2.88 | 3.70 | 3.43 | 1.44 | 0.20 | 0.20 | — |
Average Assets |
84.85 | 6.23 | 6.38 | 15.26 | 12.00 | 0.64 | 0.11 | — |
Average Common Equity |
4.16 | (0.19) | 2.44 | 11.82 | 8.50 | (2.25) | (2.25) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates